Exploring Immunotherapy Approaches in Unresectable, Nonmetastatic Hepatocellular Carcinoma

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss current standards for unresectable, nonmetastatic hepatocellular carcinoma.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss data for lenvatinib, pembrolizumab, and TACE from LEAP-012 in HCC.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss implications of China’s approval of lenvatinib, pembrolizumab, and TACE for unreseactable, nonmetastatic HCC.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss the use of systemic therapy to achieve downstaging in unreeseactable, nonmetastatic HCC.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss novel treatment approaches being explored in unreseactable, nonmetastatic HCC.

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss ongoing trials in unreseactable, nonmetastatic HCC.